France converted to universal pathogen reduced (PR; amotosalen/UVA) platelets in 2017 and extended platelet component (PC) shelf‐life from 5‐ to 7‐days in 2018 and 2019. Annual national hemovigilance (HV) reports… Click to show full abstract
France converted to universal pathogen reduced (PR; amotosalen/UVA) platelets in 2017 and extended platelet component (PC) shelf‐life from 5‐ to 7‐days in 2018 and 2019. Annual national hemovigilance (HV) reports characterized longitudinal PC utilization and safety over 11 years, including several years prior to PR adoption as the national standard of care.
               
Click one of the above tabs to view related content.